Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 12 studies | 26% ± 8% | |
brain | 9 studies | 34% ± 18% | |
peripheral blood | 7 studies | 23% ± 8% | |
intestine | 6 studies | 22% ± 10% | |
eye | 5 studies | 27% ± 12% | |
liver | 5 studies | 36% ± 17% | |
adipose | 4 studies | 22% ± 5% | |
pancreas | 3 studies | 39% ± 18% | |
placenta | 3 studies | 49% ± 4% | |
heart | 3 studies | 19% ± 1% | |
bone marrow | 3 studies | 22% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 9018.83 | 459 / 459 | 100% | 199.85 | 1118 / 1118 |
esophagus | 100% | 9062.38 | 1445 / 1445 | 100% | 149.14 | 183 / 183 |
intestine | 100% | 7528.84 | 966 / 966 | 100% | 139.94 | 527 / 527 |
ovary | 100% | 6477.00 | 180 / 180 | 100% | 113.28 | 430 / 430 |
prostate | 100% | 7178.66 | 245 / 245 | 100% | 177.03 | 502 / 502 |
stomach | 100% | 5364.45 | 359 / 359 | 100% | 137.15 | 286 / 286 |
uterus | 100% | 7128.13 | 170 / 170 | 100% | 157.82 | 458 / 459 |
liver | 100% | 8314.16 | 226 / 226 | 100% | 119.33 | 405 / 406 |
lung | 100% | 7726.95 | 576 / 578 | 100% | 149.03 | 1155 / 1155 |
thymus | 100% | 6555.23 | 652 / 653 | 100% | 208.09 | 603 / 605 |
pancreas | 100% | 5410.92 | 328 / 328 | 99% | 111.32 | 177 / 178 |
bladder | 100% | 8429.10 | 21 / 21 | 99% | 139.16 | 501 / 504 |
brain | 99% | 5761.79 | 2606 / 2642 | 100% | 115.89 | 705 / 705 |
skin | 100% | 14039.98 | 1809 / 1809 | 99% | 116.70 | 465 / 472 |
kidney | 100% | 6009.29 | 89 / 89 | 97% | 90.00 | 877 / 901 |
adrenal gland | 100% | 7722.07 | 258 / 258 | 97% | 103.24 | 222 / 230 |
adipose | 100% | 10025.96 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 114.19 | 29 / 29 |
muscle | 100% | 16823.70 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 4653.76 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 174.70 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 63.41 | 1 / 1 |
blood vessel | 100% | 6849.82 | 1334 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 96% | 7292.58 | 894 / 929 | 0% | 0 | 0 / 0 |
heart | 95% | 5868.72 | 820 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 95% | 78.98 | 76 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0032434 | Biological process | regulation of proteasomal ubiquitin-dependent protein catabolic process |
GO_0007283 | Biological process | spermatogenesis |
GO_0048568 | Biological process | embryonic organ development |
GO_0098761 | Biological process | cellular response to interleukin-7 |
GO_0006289 | Biological process | nucleotide-excision repair |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0000502 | Cellular component | proteasome complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0071942 | Cellular component | XPC complex |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0070628 | Molecular function | proteasome binding |
GO_0003697 | Molecular function | single-stranded DNA binding |
GO_0061629 | Molecular function | RNA polymerase II-specific DNA-binding transcription factor binding |
GO_0031593 | Molecular function | polyubiquitin modification-dependent protein binding |
GO_0140612 | Molecular function | DNA damage sensor activity |
GO_0005515 | Molecular function | protein binding |
GO_0043130 | Molecular function | ubiquitin binding |
GO_0003684 | Molecular function | damaged DNA binding |
Gene name | RAD23B |
Protein name | Alternative protein RAD23B RAD23 homolog B, nucleotide excision repair protein UV excision repair protein RAD23 homolog B (HR23B) (hHR23B) (XP-C repair-complementing complex 58 kDa protein) (p58) |
Synonyms | |
Description | FUNCTION: Multiubiquitin chain receptor involved in modulation of proteasomal degradation. Binds to polyubiquitin chains. Proposed to be capable to bind simultaneously to the 26S proteasome and to polyubiquitinated substrates and to deliver ubiquitinated proteins to the proteasome. May play a role in endoplasmic reticulum-associated degradation (ERAD) of misfolded glycoproteins by association with PNGase and delivering deglycosylated proteins to the proteasome.; FUNCTION: Involved in global genome nucleotide excision repair (GG-NER) by acting as component of the XPC complex. Cooperatively with CETN2 appears to stabilize XPC. May protect XPC from proteasomal degradation.; FUNCTION: The XPC complex is proposed to represent the first factor bound at the sites of DNA damage and together with other core recognition factors, XPA, RPA and the TFIIH complex, is part of the pre-incision (or initial recognition) complex. The XPC complex recognizes a wide spectrum of damaged DNA characterized by distortions of the DNA helix such as single-stranded loops, mismatched bubbles or single-stranded overhangs. The orientation of XPC complex binding appears to be crucial for inducing a productive NER. XPC complex is proposed to recognize and to interact with unpaired bases on the undamaged DNA strand which is followed by recruitment of the TFIIH complex and subsequent scanning for lesions in the opposite strand in a 5'-to-3' direction by the NER machinery. Cyclobutane pyrimidine dimers (CPDs) which are formed upon UV-induced DNA damage esacpe detection by the XPC complex due to a low degree of structural perurbation. Instead they are detected by the UV-DDB complex which in turn recruits and cooperates with the XPC complex in the respective DNA repair. In vitro, the XPC:RAD23B dimer is sufficient to initiate NER; it preferentially binds to cisplatin and UV-damaged double-stranded DNA and also binds to a variety of chemically and structurally diverse DNA adducts. XPC:RAD23B contacts DNA both 5' and 3' of a cisplatin lesion with a preference for the 5' side. XPC:RAD23B induces a bend in DNA upon binding. XPC:RAD23B stimulates the activity of DNA glycosylases TDG and SMUG1. |
Accessions | L8EA19 Q5W0S5 H0Y579 P54727 ENST00000416373.6 [P54727-2] ENST00000442587.1 ENST00000419616.5 ENST00000358015.8 [P54727-1] Q5W0S4 ENST00000457811.1 |